omarigliptin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| dipeptidyl aminopeptidase-IV inhibitors | 5054 | 1226781-44-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 28, 2015 | PMDA | MSD K.K. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
None
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.94 | Basic |
| pKa2 | 4.58 | Basic |
| pKa3 | 0.2 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Dipeptidyl peptidase 4 | Enzyme | INHIBITOR | Ki | 9.10 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 4.41 | CHEMBL | |||||
| Dipeptidyl peptidase 4 | Enzyme | IC50 | 7.36 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| CVP59Q4JE1 | UNII |
| D10317 | KEGG_DRUG |
| C4279587 | UMLSCUI |
| CHEBI:134735 | CHEBI |
| CHEMBL2105762 | ChEMBL_ID |
| 46209133 | PUBCHEM_CID |
| DB11992 | DRUGBANK_ID |
| 9586 | INN_ID |
| C587539 | MESH_SUPPLEMENTAL_RECORD_UI |
| 8402 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
None